Using personalized prognosis in the treatment of relapsing multiple sclerosis: A practical guide

dc.contributor.authorVan Wijmeersch Bart
dc.contributor.authorHartung Hans-Peter
dc.contributor.authorVermersch Patrick
dc.contributor.authorPugliatti Maura
dc.contributor.authorPozzilli Carlo
dc.contributor.authorGrigoriadis Nikolaos
dc.contributor.authorAlkhawajah Mona
dc.contributor.authorAiras Laura
dc.contributor.authorLinker Ralf
dc.contributor.authorOreja-Guevara Celia
dc.contributor.organizationfi=InFLAMES Lippulaiva|en=InFLAMES Flagship|
dc.contributor.organizationfi=kliiniset neurotieteet|en=Clinical Neurosciences|
dc.contributor.organizationfi=tyks, vsshp|en=tyks, varha|
dc.contributor.organization-code1.2.246.10.2458963.20.68445910604
dc.contributor.organization-code1.2.246.10.2458963.20.74845969893
dc.converis.publication-id176943213
dc.converis.urlhttps://research.utu.fi/converis/portal/Publication/176943213
dc.date.accessioned2022-11-29T15:53:09Z
dc.date.available2022-11-29T15:53:09Z
dc.description.abstractThe clinical course of multiple sclerosis (MS) is highly variable among patients, thus creating important challenges for the neurologist to appropriately treat and monitor patient progress. Despite some patients having apparently similar symptom severity at MS disease onset, their prognoses may differ greatly. To this end, we believe that a proactive disposition on the part of the neurologist to identify prognostic "red flags" early in the disease course can lead to much better long-term outcomes for the patient in terms of reduced disability and improved quality of life. Here, we present a prognosis tool in the form of a checklist of clinical, imaging and biomarker parameters which, based on consensus in the literature and on our own clinical experiences, we have established to be associated with poorer or improved clinical outcomes. The neurologist is encouraged to use this tool to identify the presence or absence of specific variables in individual patients at disease onset and thereby implement sufficiently effective treatment strategies that appropriately address the likely prognosis for each patient.
dc.identifier.olddbid190302
dc.identifier.oldhandle10024/173393
dc.identifier.urihttps://www.utupub.fi/handle/11111/34787
dc.identifier.urlhttps://www.frontiersin.org/articles/10.3389/fimmu.2022.991291/full
dc.identifier.urnURN:NBN:fi-fe2022112968064
dc.language.isoen
dc.okm.affiliatedauthorAiras, Laura
dc.okm.affiliatedauthorDataimport, tyks, vsshp
dc.okm.discipline3112 Neurosciencesen_GB
dc.okm.discipline3124 Neurology and psychiatryen_GB
dc.okm.discipline3112 Neurotieteetfi_FI
dc.okm.discipline3124 Neurologia ja psykiatriafi_FI
dc.okm.internationalcopublicationinternational co-publication
dc.okm.internationalityInternational publication
dc.okm.typeA2 Scientific Article
dc.publisherFRONTIERS MEDIA SA
dc.publisher.countrySwitzerlanden_GB
dc.publisher.countrySveitsifi_FI
dc.publisher.country-codeCH
dc.relation.articlenumber991291
dc.relation.doi10.3389/fimmu.2022.991291
dc.relation.ispartofjournalFrontiers in immunology
dc.relation.volume13
dc.source.identifierhttps://www.utupub.fi/handle/10024/173393
dc.titleUsing personalized prognosis in the treatment of relapsing multiple sclerosis: A practical guide
dc.year.issued2022

Tiedostot

Näytetään 1 - 1 / 1
Ladataan...
Name:
fimmu-13-991291.pdf
Size:
610.79 KB
Format:
Adobe Portable Document Format